An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia.
Bogdan MuresanCarla M MamoloJoseph C CappelleriEric LeipAndrea ViqueiraBart HeegPublished in: Current medical research and opinion (2021)
Overall, in these analyses bosutinib demonstrates equivalent efficacy to nilotinib and dasatinib in the treatment of patients with newly diagnosed CP-CML.
Keyphrases